Table 2.
Incidence of adjudicated drug-related ILD/pneumonitis in the DESTINY-Breast03 trial [50]
| Population | Treatment arm | Adjudicated drug-related ILD/pneumonitis, n (%) | |||||
|---|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | Any grade | ||
| Overall | T-DXd (n = 257) | 7 (2.7) | 18 (7.0) | 2 (0.8) | 0 | 0 | 27 (10.5) |
| T-DM1 (n = 261) | 4 (1.5) | 1 (0.4) | 0 | 0 | 0 | 5 (1.9) | |
| Asian patients | T-DXd (n = 147) | 5 (3.4) | 10 (6.8) | 1 (0.7) | 0 | 0 | 16 (10.9) |
| T-DM1 (n = 159) | 3 (1.9) | 1 (0.6) | 0 | 0 | 0 | 4 (2.5) | |
| Japanese patients | T-DXd (n = 36) | 4 (11.1) | 4 (11.1) | 0 | 0 | 0 | 8 (22.2) |
| T-DM1 (n = 31) | 2 (6.5) | 1 (3.2) | 0 | 0 | 0 | 3 (9.7) | |
ILD interstitial lung disease, T-DM1 trastuzumab emtansine, T-DXd trastuzumab deruxtecan